Topic: Pharmaceuticals

Rouse highlights some of the most important pharma patent decisions issued by Southeast Asian courts in the past four years

Antitrust challenges against pharma patent strategies continue to escalate

Appellate court hands down guidance on induced infringement cases

Alexion Pharmaceuticals denied PI requests against biosimilar eculizumab producers Amgen and Samsung Bioepis

27 June 2024

Regeneron’s PI against Samsung Bioepis in ongoing aflibercept litigation follows several failed attempts to obtain interim bans by biologic patentees

18 June 2024

Advice for biotech-pharma innovators to manage IP strategy while taking the risky gamble of introducing new drugs or medical devices to market

14 June 2024

Pendulum swings in favour of local generic drugmaker Natco in long-running Indian pharma dispute against Novartis

12 June 2024

The wildly inconsistent decisions produced by the region’s national courts underscore the potential appeal of the Unified Patent Court

07 June 2024

Docket Navigator research shows unclean hands unenforceability is exceedingly uncommon – succeeding in just three other cases since 2008

03 June 2024

Huawei and pharma giant Hengrui Pharmaceuticals are among the top patent filers in Latin America’s hottest IP jurisdiction

30 May 2024

The German company remains involved in more than 70 proceedings across 20-plus European countries

28 May 2024

Saturday Opinion: Use of the pan-European court by drug patentees picks up pace as Sanofi takes aim at four generics

25 May 2024

But big money pharma patent damages have a habit of being overturned

21 May 2024

Unlock unlimited access to all IAM content